

VAM 2023: Repurposing, a paradigm shift in access to treatment

Tuesday 7 November 2023

08.00
09.00  Registration and welcome coffee

09.00
09.15  Opening address

Arun Narayan, Chair of the Value Added Medicines Sector Group, Medicines for Europe

09.15
09.30  Keynote speech

Cristina Montané, Citizen Participation Director, Foro Español de Pacientes (FEP)

09.30
11.00  Unlocking the potential of repurposing through the new pharmaceutical legislation

The proposal for a new pharmaceutical legislation marks an important step in recognising the value of off-patent innovation by including several measures specifically targeted to it. What are these measures and what is their impact? Are there any roadblocks to applying them in practice? Throughout this session, we will aim to answer these questions and discuss how to harness the potential of repurposing to bring significant benefit to patients, healthcare professionals and health systems as a whole.

Moderator: Adrian van den Hoven, Director General, Medicines for Europe

Presentation

- **Julia Schmitz**, Policy Officer, European Commission's Directorate-General for Health and Food Safety (Unit SANTE.D1)

Panellists

- **Antonella Cardone**, CEO, Cancer Patients Europe
- **Nóra Gyimesi**, Chair of pre-filled syringes Special Interest Group, EAHP
- **Hans Platteeuw**, Executive Director, Galenicap
- **Arun Narayan**, Chair of the Value Added Medicines Sector Group, Medicines for Europe

11.00
11.30  Networking coffee break

11.30
12.30



The tools needed to make repurposing a reality

Repurposing has been recognised as an important drug development strategy to deliver safe, effective, and affordable medicines which target patient needs. This has been further explored through the STAMP repurposing pilot by the European Medicines Agency. This session will cover the experiences both within the STAMP project, as well as independently of it, discussing the practical implications of bringing a new indication to the label, the challenges faced by all stakeholders and potential tools to address them.

Moderator: Raluca Radu, Value Added Medicines Policy Manager, Medicines for Europe

Presentations

- **Christelle Bouygues**, Regulatory Affairs Senior Officer, European Medicines Agency (EMA)
- **Patricia Vandamme**, Policy Officer, Anticancer Fund
- **Heleen van der Meer**, Senior Programme Manager International Drug Repurposing, ZonMw
- **Vaibhav Sharma**, Head of Value Added Products, Zentiva

12.30
13.15



SPOTLIGHT SESSION: The evolving Value Added Medicines sector

Moderator: Klara Marton, Vice-Chair of the Value Added Medicines Sector Group

Presentation: Aurelio Arias, Director, IQVIA Thought Leadership

13.15
14.30



Networking buffet lunch

14.30
16.00



Barriers and facilitators for affordable innovation

The EU is the second largest market for value added medicines, however it accounts for only about 1/4 of that of the US. Companies within the EU continue to invest in repurposing, finding new and improved uses of off patent medicines, despite the benefits of these products not being recognised in most cases. During this session we will map out the existing barriers and facilitators, discuss how companies currently navigate this system and jointly discuss what are possible policy options to enhance access to affordable innovation.

Moderator: Maja Graf, Associate Director Policy & Market Access, Medicines for Europe

Presentations

- **Zsuzsanna Petykó**, Syreon Research Institute
- **Laurent Martin**, Chief Pharmaceutical Affairs Officer, Orphelia PHARMA

Panellists

- **Pan Pantziarka**, Director of Drug Repurposing, Anticancer Fund
- **James Burt**, Vice-chair of the VAM Sector Group and CEO Pharmanovia
- **Cesar Hernández García**, Director General, Common Portfolio of the NHS and Pharmacy, Spanish Ministry of Health

5th VALUE ADDED MEDICINES
CONFERENCE
THE HOTEL, BRUSSELS
7 NOVEMBER 2023

#VAM23

16.00
16.30



Networking coffee break

16.30
17.15



SPOTLIGHT SESSION: Looking to the future: health data & new ways of evidence generation

With a growing pool of real-world patient data available, companies and researchers are more easily able to explore novel uses of existing medicines. Real-world evidence also plays an increasingly important role for regulators and value assessments of health technologies, as it can generate valuable insight and complement data obtained from clinical trials. In the course of this session, we will cover the current initiatives in the field and discuss practical examples of how real-world evidence is being used and its potential for the future.

Moderator: Susana Almeida, Clinical Development and Safety Director, Medicines for Europe

Presentation

- **Andrej Segec**, DARWIN EU® Project manager, Data Analytics and Methods Task Force, European Medicines Agency

17.15
17.30



Conference closure

James Burt, Vice-chair of the VAM Sector Group and CEO Pharmanovia

PLATINUM SPONSOR



MEDIA PARTNER



For further information on the conference and to register

[5th Value Added Medicines Live Conference | Medicines for Europe](#)